Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-11-24
2009-12-01
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C514S012200
Reexamination Certificate
active
07625716
ABSTRACT:
The c-Myc oncogene is bound by p19Arf, which inhibits c-Myc's ability to transform cells while augmenting apoptosis. This provides the basis for screening assays that examine the ability of various candidate substances to promote p19Arf interactions, or to substitute therefor.
REFERENCES:
patent: 5580721 (1996-12-01), Brent et al.
patent: 6586203 (2003-07-01), Sherr et al.
patent: 2002/0045192 (2002-04-01), Kriwacki et al.
patent: WO 00/08153 (2000-02-01), None
patent: WO 02/20770 (2002-03-01), None
patent: WO 02/65116 (2002-08-01), None
Matsumura et al. Cell Cycle 2:4, Jul./Aug. 2003, p. 333-338.
Eischen et al. Genes and Development 13, p. 2658-2669, 1999.
Cleveland et al., “Antagonism of Myc functions by Afr”,Cancer Cell,6:309-311, 2004.
Qi et al., “p19ARF directly and differentially controls the functions of c-Myc independently of p53”,Nature,431:712-717, 2004.
Amanullay et al., “p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation,”Oncogene,19:2967-2977, 2000.
Bates et al., “p14ARFliks the tumour suppressors RB and p53,”Nature,395:124-125, 1998.
Berg et al., “Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts,”Proc. Natl. Acad. Sci.,USA, 99:3830-3835, 2002.
Bergsmedh et al., “Loss of the p21(Cip1/Waf1) cyclin kinase inhibitor results in propagation of horizontally transferred DNA,”Cancer Res.,62(2):575-579, 2002.
Carlson et al., “Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation,”Oncogene,21(24):3827-3835, 2002.
Conzen et al., “Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis,”Mol Cell Biol,20(16):6008-6018, 2000.
Datta et al., “Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc,”J. Biol. Chem.,279:36698-36707, 2004.
Eischen et al., “Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis,”Genes Dev,13:2658-2669,1999.
Fukasawa et al., “Genomic instability and apoptosis are frequent in p53 deficient young mice,”Oncogene,15:1295-1302, 1997.
Haviernik et al., “Consistent inactivation of p19(Arf) but not p15(Ink4b) in murin myeloid cells transformed in vivo by deregulated c-Myc,”Oncogene,22(11):1600-1610, 2003.
Honda and Yasuda, “Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53,”EMBO J,18(1):22-27, 1999.
Inoue et al., “Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas,”Genes Dev,15(22):2934-2939, 2001.
Jacobs et al., “Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF,”Genes Dev,13(20):2678-2690, 1999.
Jacobs et al., “The oncogene and polycomb-group bmi-1 regulates cell proliferation and senescence through the ink4a locus,”Nature,397(6715):164-168, 1999.
Kamijo et al., “Tumor spectrum in ARF-deficient mice,”Cancer Res.,59:2217-2222, 1999.
Korgaonkar et al., “ARF function does not require p53 stabilization or Mdm2 relocalization,”Mol. Cell Biol.,2(1):196-206, 2002.
Lenahan and Ozer, “Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts,”Oncogene,12(9):1847-1854, 1996.
Lindstrom and Wiman, “Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts,”Oncogene,22(32):4993-5005, 2003.
Lohrum et al., “Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization,” Curr Biol, 10(9):539-542, 2000.
Midgley et al., “An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo,” Oncogene, 19(19):2312-2323, 2000.
Ng, “Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies,”Apoptosis,7(3):261-270, 2002.
Oster etal., “Functional analysis of the N-terminal domain of the Myc oncoprotein,” Oncogene, 22:1998-2010, 2003.
Peeper et al., “A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence,”Nat Cell Biol,4(2):148-153, 2002.
Pendergast, “Mechanisms of apoptosis by c-Myc,”Oncogene,19(19):2967-2987, 1999.
Pomerantz et al., “The Ink4a tumor suppressor gene product, pl9Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53,”Cell,92:713-723, 1998.
Qi et al., “CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells,”Proc. Natl. Acad. Sci.,USA, 100(2):633-638, 2003.
Rasko et al., “Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF,”Cancer Res.,61(16):6002-6007, 2001.
Raveh et al., “DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation,”Nat Cell Biol,3(1):1-7, 2001.
Soucek et al., “Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis,”Cancer Res.,62:3507-3510, 2002.
Trudel et al., “C-MYC-induced apoptosis in polycystic kidney disease is Bc1-2 and p53 independent,”J Exp Med,186:1873-1884, 1997.
Tsuji et al., “p53-independent apoptosis is induced by the p19ARFtumor suppressor,”Biochim Biophys Res Commun,295:621-629, 2002.
Weber et al., “Nucleolar Arf sequesters Mdm2 and activates p53,”Nat Cell Biol,1(1):20-26, 1999.
Weber et al., “p53-independent functions of the p19ARFtumor suppressor,”Genes Dev.,14(18):2358-2365, 2000.
Wood et al., “Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor,”Endocrinology,143(2):347-359, 2002.
Xiao et al., “Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis,”Genes Dev.,12:3803-3808, 1998.
Zhang et al., “ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways,”Cell,92:725-734, 1998.
Zindy et al., “Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization,”Genes Dev.,12:2424-2433, 1998.
Fulbright & Jaworski
Helms Larry R.
Natarajan Meera
Vanderbilt University
LandOfFree
Methods for assessing p19-Arf interactions in cMyc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for assessing p19-Arf interactions in cMyc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for assessing p19-Arf interactions in cMyc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085295